IF THIS NEWSLETTER DOESN’T LOOK RIGHT, CLICK HERE TO SEE THE WEB VERSION
7th Annual
THE
Diabetes mellitus and
cardiovascular risk
galien forum
Next Generation
Antimicrobials
Precision
Medicine
2
2016
Fight Against
Cancer
Keynote
US Health Reform
Molecular
Scissors
New York City, October 27, 2016
A LEADING
GLOBAL HEALTHCARE &
LIFE SCIENCE EVENT
THE
Alexandria Center For Life Science
450 East 29th Street, between 1st Avenue and the East River, NYC
IN THE PROGRAM:
07:15 – 07:45 am
Registration and Coffee
07:45 – 08:00 am
Welcome
08:00 – 09:15 am
Diabetes mellitus and cardiovascular risk –
on the rise, fall and novel possibilities with glucose lowering drugs
Bengt Samuelsson, MD, PhD, Chair, Nobel Laureate, Former President of Karolinska Institute
and Former chairman of the Nobel Foundation
Daniel J. Drucker, Senior Scientist, Lunenfeld Tanenbaum Research Institute Mt. Sinai Hospital Toronto
Ontario, Canada
Michael Mark, Vice President and Global Head of Cardio Metabolic Diseases Research Boehringer
Pharma GmbH &
Ingelheim
Co. KG Research
Lars Rydén, MD, Dr h.c., HMRCP, FESC, FACC, FAHA, Senior Professor of Cardiology at Karolinska
Institute, Stockholm, Sweden
at the
Lunenfeld-Tanenbaum Research Institute, Mount Sinai
Bernard Zinman, MD, Senior Scientist
Sinai Centre
for Diabetes.
of the Leadership
Mount Sinai Hospital, Toronto, Ontario
Hospital and Director
09:15 – 10:20 am
Next Generation Antimicrobials – Shaping Policy to Develop New
Business Models
Joel S. Marcus, Co-Moderator, Chairman, Chief Executive Officer & Founder, Alexandria Real Estate
Equities, Inc./Alexandria Venture Investments; Co-Founder, Alexandria Summit
Lynne Zydowsky, PhD, Co-Moderator, President & Co-Founder, Alexandria Summit; Chief Science
Advisor to the CEO, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments
Michael W. Bonney, Retired Chief Executive Officer, Cubist Pharmaceuticals Inc.; Advisor, UK Review on
Antimicrobial Resistance
Maria C. Freire, PhD, President & Executive Director, Foundation for the National Institutes of Health
Jonathan S. Leff, MBA, Partner, Deerfield Management; Chairman, Deerfield Institute
Mark McClellan, MD, PhD, Director, Duke-Robert J. Margolis Center for Health Policy & Robert J. Margolis
Professor of Business, Medicine, and Health Policy, Duke University
10:20 – 10:45 am
Coffee Break
10:45 – 11:50 am
Precision Medicine: Delivering on the Promise
Mikael Dolsten, MD, PhD, Chair, President, Worldwide Research and Development, Pfizer Inc.
David Feltquate, MD, PhD, Vice President, Immuno-Oncology Development, Bristol-Myers Squibb
Michel Sadelain, MD, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
Jonathan Sheldon, PhD, Global Vice President, Healthcare, Health Sciences Global Business Unit, Oracle
Philip Vickers, PhD, Global Head of Research and Development, Shire plc
11:50 am – 12:55 pm
Promise - and Politics - in the Fight Against Cancer
Craig Thompson, MD, Chair, President and CEO, Memorial Sloan-Kettering Cancer Center David Epstein,
division head, Novartis Pharmaceuticals
David Epstein, Former CEO and Division Head Novartis Pharmaceuticals
Margaret A. Hamburg, MD, Former Commissioner of the U.S. Food and Drug Administration
F
Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology
12:55 – 01:45 pm
Lunch Break
01:45 – 02:45 pm
Keynote
Mark McClellan, MD, PhD, Director, Duke-Robert J. Margolis Center for Health Policy & Robert J.
Margolis Professor of Business, Medicine, and Health Policy, Duke University
P. Roy Vagelos, MD, Chairman of Regeneron Pharmaceuticals and Retired Chairman and Chief Executive
Officer of Merck & Co., Inc. will introduce Dr. McClellan and moderate an audience Q&A on the next
chapter in the global politics of health care
02:45 – 03:50 pm
Molecular Scissors: What Can We Expect from Gene Editing?
George Yancopoulos, MD, PhD, Chair, Chief Scientific Officer of Regeneron Pharmaceuticals and
President, Regeneron Laboratories
Charles Albright, CSO, Editas
John Leonard, CMO, Intellia Therapeutics
Sandy Macrae, President and CEO, Sangamo BioSciences
)RUPRUHLQIRUPDWLRQ
SOHDVHFRQWDFWRXURIILFHV
IRUXP#JDOLHQIRXQGDWLRQRUJ
6KDUH
5(*,67(512: